Last reviewed · How we verify
STN1010904 ophthalmic suspension 0.1% BID
STN1010904 ophthalmic suspension 0.1% BID is a Small molecule drug developed by Santen Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | STN1010904 ophthalmic suspension 0.1% BID |
|---|---|
| Sponsor | Santen Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STN1010904 ophthalmic suspension 0.1% BID CI brief — competitive landscape report
- STN1010904 ophthalmic suspension 0.1% BID updates RSS · CI watch RSS
- Santen Inc. portfolio CI
Frequently asked questions about STN1010904 ophthalmic suspension 0.1% BID
What is STN1010904 ophthalmic suspension 0.1% BID?
STN1010904 ophthalmic suspension 0.1% BID is a Small molecule drug developed by Santen Inc..
Who makes STN1010904 ophthalmic suspension 0.1% BID?
STN1010904 ophthalmic suspension 0.1% BID is developed by Santen Inc. (see full Santen Inc. pipeline at /company/santen-inc).
What development phase is STN1010904 ophthalmic suspension 0.1% BID in?
STN1010904 ophthalmic suspension 0.1% BID is in Phase 2.